Saturday, 16 November 2024, Liverpool, UK
Recording available soon
Rhythm sponsored satellite symposium at ESPE 2024
Early treatment of hyperphagia and early-onset, severe obesity in children with rare melanocortin-4 receptor (MC4R) pathway diseases
KEY TOPICS:
The MC4R pathway and genetic variants, focusing on monogenic disease
Overview of Bardet-Biedl syndrome (BBS) leading to hyperphagia and early-onset, severe obesity
Treatment of children with BBS
Professor Sadaf Farooqi
Please login or signup to unlock the videosRhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
Professor Philip Beales
Please login or signup to unlock the videosRhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
Dr Metin Cetiner
Please login or signup to unlock the videosRhythm Pharmaceuticals is leveraging a IQVIA's Healthcare Professional Authentication solution to identify your eligibility to access this video content. If you already have an IQVIA account using it with other healthcare providers, please click 'Login' otherwise click 'Signup'.
Professor Sadaf Farooqi
(UK)
Professor Philip Beales
(UK)
Dr Metin Cetiner
(Germany)
This promotional symposium is organised and funded by Rhythm Pharmaceuticals Netherlands B.V. and is intended for healthcare professionals only.